PMHNP Scope of Practice for Narcolepsy in California

If you’re a psychiatrist or PMHNP treating—or considering treating—narcolepsy patients via telehealth, you’re navigating one of the more complex corners of telepsychiatry regulation. Narcolepsy often requires Schedule II stimulants like Adderall or methylphenidate, plus other controlled medications like modafinil and sodium oxybate. The question isn’t just ‘can I prescribe these remotely?’—it’s ‘which states allow it, under what conditions, and for how long?’

Here’s the reality: as of early 2026, you can prescribe narcolepsy medications via telehealth in most states, thanks to federal COVID-era flexibilities that have been extended through December 31, 2026. But the rules are temporary, state-dependent, and about to change. If you’re building a telehealth practice around sleep disorders or expanding your psychiatric services to include narcolepsy management, you need to understand both the federal DEA landscape and the state-by-state quirks that can make or break your compliance.

Let’s cut through the noise and focus on what actually matters for your practice.

The Federal Baseline: DEA Telemedicine Rules and the Ryan Haight Act

Normally, federal law—specifically the Ryan Haight Online Pharmacy Consumer Protection Act of 2008—requires at least one in-person medical evaluation before you can prescribe any controlled substance via the internet or telemedicine. This applies to everything from Schedule II stimulants (amphetamines, methylphenidate) to Schedule IV wakefulness agents (modafinil, armodafinil) used in narcolepsy treatment.

The Ryan Haight exceptions are narrow: you can prescribe controlled substances via telehealth if the patient is in a DEA-registered hospital or clinic, if they were referred by a physician who saw them in person, if you’re covering for another provider who examined them, or if they’re in the VA/IHS system. For most private telepsychiatry practices, none of these apply.

The COVID-Era Waiver (Still in Effect Through 2026)

In March 2020, the DEA waived the in-person exam requirement to prevent care disruptions during the pandemic. This waiver allowed providers to prescribe Schedule II-V controlled substances—including narcolepsy medications—via audio or video telehealth without ever meeting the patient face-to-face, as long as the prescription was otherwise legitimate and compliant with all other Controlled Substances Act requirements (state licensure, DEA registration, standard of care).

The federal Public Health Emergency ended in May 2023, but the DEA and HHS have repeatedly extended the telehealth flexibilities. The most recent extension, announced January 2, 2026, runs through December 31, 2026 (www.hhs.gov). This gives providers a stable runway through the end of 2026 to prescribe controlled narcolepsy medications via telehealth.

What this means practically: Right now, you can evaluate a new narcolepsy patient on video, diagnose them (ideally in coordination with sleep study results), and e-prescribe stimulants, modafinil, or sodium oxybate—all remotely. You don’t need an initial in-person visit under federal law. But you must:

• Hold an active DEA registration with Schedule II authority (if prescribing stimulants)
• Be licensed in the state where the patient is located
• Follow standard prescribing practices (checking state prescription drug monitoring programs, documenting clinical rationale, e-prescribing where required)
• Comply with any additional state-level restrictions (more on this below)

What Happens After December 31, 2026?

The DEA is working on permanent telemedicine rules. An initial 2023 proposal would have required an in-person visit after an initial 30-day telemedicine prescription for most Schedule II drugs, and would have prohibited telehealth initiation of Schedule II stimulants without any in-person exam. That proposal was heavily criticized—over 38,000 public comments opposed it—and the DEA pulled back to reconsider (www.dea.gov).

The only finalized telehealth-specific rules so far (as of January 2025) are narrow carve-outs: one allowing buprenorphine prescribing for opioid use disorder via telemedicine without an in-person exam, and one for VA patients continuing care remotely (www.dea.gov). Narcolepsy has no special exception yet.

Prepare for change: It’s likely that permanent rules will require some in-person component—possibly an initial exam within 30-90 days, or periodic in-person visits for ongoing prescriptions. Smart providers are already building hybrid models: partnering with local clinics for physical exams or sleep studies, or planning telehealth-to-in-person handoffs for diagnostic confirmation.

Bottom line: You have a clear path to prescribe narcolepsy meds via telehealth through 2026. After that, expect tighter restrictions and plan your practice model accordingly.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality: Where the Rules Actually Bite

Federal law sets the floor, but states can impose their own restrictions—and several do, especially around Schedule II stimulants. Here’s how the six major telehealth markets stack up for narcolepsy care:

California: NP Independence Meets Telehealth Flexibility

What you can do: Psychiatrists have full authority to diagnose and treat narcolepsy via telehealth, including prescribing all controlled medications. California law doesn’t impose any in-person exam requirement beyond federal law, so you’re good through 2026 under the DEA waiver.

NP scope: California recently implemented AB 890, which grants full practice authority to experienced NPs. As of 2023, NPs with ≥4,600 hours of supervised practice can practice independently—including diagnosing narcolepsy and prescribing Schedule II stimulants—without a collaborating physician (rxagent.co). You need to complete specified pharmacology training on controlled substances and obtain a furnishing number with Schedule II authority (rn.ca.gov).

Key compliance points:

• Mandatory CURES PDMP check before every controlled substance prescription (and at least every 4 months for ongoing therapy)
• E-prescribing required for controlled substances
• Document the telehealth exam as thoroughly as an in-person visit

Why this matters: California is one of the few states where an experienced PMHNP can run an independent narcolepsy telehealth practice without physician oversight. That’s a game-changer for expanding access in underserved areas.

Texas: Physician-Dependent and Video-Only

What you can do: Psychiatrists can prescribe narcolepsy medications via telehealth using live two-way audio-visual communication. Phone calls alone won’t cut it for controlled substances—Texas requires video.

NP scope: Here’s where it gets restrictive. Texas APRNs cannot prescribe Schedule II controlled substances in outpatient settings, period (www.tmb.state.tx.us). The only exceptions are hospital admissions (≥24 hours), emergency departments, or terminally ill hospice patients—and even then, the prescription must be filled at the hospital or hospice pharmacy.

This means a Texas PMHNP cannot prescribe Adderall or methylphenidate for narcolepsy to an outpatient. They can prescribe modafinil (Schedule IV) under a physician delegation agreement, but for Schedule II stimulants, you need an MD to write the prescription.

Practice model: If you’re a telehealth platform operating in Texas with NPs, you need psychiatrists on staff to handle stimulant prescriptions, or you need to arrange in-person physician consultations for patients who require Schedule IIs.

Other Texas quirks:

• State law bans telehealth prescribing of controlled substances for chronic pain management (but narcolepsy isn’t classified as chronic pain, so this doesn’t apply) (www.cchpca.org)
• Physicians can supervise at most 7 NPs/PAs in outpatient settings
• Mandatory Texas PMP check before any controlled substance prescription

Florida: The Telehealth Stimulant Ban for Non-Psychiatric Conditions

Florida is the most restrictive state in our analysis. Florida law explicitly prohibits prescribing Schedule II controlled substances via telehealth for most conditions. The exceptions are limited to:

1. Treating a psychiatric disorder
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

(www.leg.state.fl.us)

The problem: Narcolepsy is a neurological sleep disorder, not a psychiatric disorder. So even though narcolepsy is explicitly listed as an approved indication for prescribing amphetamines under Florida’s formulary rules, you cannot prescribe those stimulants via telehealth in Florida for narcolepsy.

Workarounds:

• Start patients on modafinil or armodafinil (Schedule IV) via telehealth—these aren’t covered by Florida’s Schedule II telehealth ban
• Arrange at least one in-person visit with the patient (or coordinate with a local provider who can examine them in person) to prescribe Schedule II stimulants compliantly
• If you’re treating comorbid conditions (e.g., ADHD or depression alongside narcolepsy), the psychiatric exception might apply—but tread carefully and document thoroughly

NP scope in Florida: Even more restrictive. Florida NPs can prescribe Schedule II controlled substances, but only for a 7-day supply unless the NP is a ‘psychiatric nurse’ (a certified PMHNP with ≥2 years of experience under a psychiatrist) treating a mental health disorder (www.flsenate.gov). Since narcolepsy isn’t a mental illness, the 7-day limit applies even to psychiatric NPs.

Bottom line: Florida is a tough market for telehealth narcolepsy care. You’ll likely need a hybrid model or rely on non-stimulant alternatives for purely remote patients.

New York: Defers to Federal Rules (For Now)

What you can do: New York finalized regulations in May 2025 that technically require an in-person exam before prescribing controlled substances via telemedicine—unless certain exceptions apply. One key exception: prescribing is allowed if it complies with federal law and DEA regulations (www.nixonpeabody.com).

Since the DEA waiver currently permits telehealth prescribing without an in-person visit, New York providers can prescribe narcolepsy medications remotely right now. If the DEA tightens the rules after 2026, New York’s in-person requirement will kick back in unless you use one of the other exceptions (e.g., patient recently examined by a consulting provider who referred them to you).

NP scope: New York is a full practice authority state for experienced NPs. After 3,600 hours of practice, PMHNPs can diagnose and treat narcolepsy independently, including prescribing Schedule II-V controlled substances. They need their own DEA registration and must register with New York’s I-STOP prescription monitoring program.

Compliance:

• Mandatory I-STOP database check before every controlled substance prescription
• E-prescribing required
• Document clinical rationale when relying on the federal telehealth exception

Why this matters: New York is one of the friendliest states for independent NP telehealth practice. An experienced PMHNP can run a narcolepsy practice entirely remotely (for now), which significantly expands access in rural upstate areas.

Pennsylvania: Collaborative Model with Supply Limits

What you can do: Psychiatrists can prescribe narcolepsy medications via telehealth. Pennsylvania has no state law banning controlled substances via telemedicine—the state defers to federal requirements.

NP scope: Pennsylvania is a restricted practice state. CRNPs (Certified Registered Nurse Practitioners) must have a collaborative agreement with a physician. They can prescribe Schedule II-V controlled substances if the collaborating physician approves, but with limits:

• Schedule II prescriptions: 30-day supply maximum (physician must be consulted for continuation beyond that)
• Schedule III-IV: 90-day supply maximum

For narcolepsy management, this means a Pennsylvania PMHNP can initiate treatment and prescribe modafinil (Schedule IV) for ongoing care, but will need physician involvement for stimulant refills or dose adjustments beyond the first month.

Recent changes: Pennsylvania removed the old 72-hour initial limit on Schedule II prescribing for NPs in 2021, aligning with the 30-day standard. The state also has no limit on how many NPs a physician can supervise (unlike Texas’s 7:1 ratio), which helps scale telehealth practices (www.pacodeandbulletin.gov).

Compliance:

• Check Pennsylvania’s PDMP before every controlled substance prescription
• E-prescribing required
• Collaborative agreement must explicitly delegate controlled substance prescribing authority

Illinois: Full Practice for Experienced NPs (With a Caveat)

What you can do: Psychiatrists have full authority to prescribe via telehealth, following federal rules.

NP scope: Illinois grants full practice authority to NPs who complete 4,000 hours of collaborative practice + 250 hours of continuing education in their specialty. Once you have FPA status, you can diagnose narcolepsy and prescribe Schedule II-V controlled substances independently—no collaborating physician required (rxagent.co).

The caveat: Illinois law requires NPs with FPA who prescribe benzodiazepines or opioids to maintain a ‘consultation relationship’ with a physician. Stimulants (amphetamines, methylphenidate) are Schedule II but aren’t opioids, so this consultation requirement likely doesn’t apply to narcolepsy stimulant prescriptions—but it’s a gray area worth clarifying with legal counsel if you’re prescribing high volumes.

Compliance:

• Apply for Illinois’s Mid-Level Practitioner Controlled Substance License in addition to your DEA registration
• Check the Illinois Prescription Monitoring Program (ILPMP) before prescribing
• E-prescribing mandatory for controlled substances (as of January 2023)

Why this matters: Illinois is another state where experienced PMHNPs can operate independently for narcolepsy care, making it attractive for telehealth expansion.

Psychiatrist vs PMHNP: Who Can Do What?

Psychiatrists (MD/DO): Full independent authority in all 50 states to diagnose narcolepsy and prescribe all necessary medications, including Schedule II stimulants, as long as you have:

• State medical license where the patient is located
• DEA registration with Schedule II authority
• Compliance with state PDMP and e-prescribing requirements

PMHNPs: Authority varies dramatically by state:

• Full practice states (CA, NY, IL with experience requirements): Can diagnose and prescribe independently once you meet the experience/training thresholds
• Reduced practice states (FL): Need physician collaboration; significant prescribing limits on Schedule IIs
• Restricted practice states (TX, PA): Need physician collaboration; in Texas, cannot prescribe Schedule IIs for outpatients at all

Scope of practice reality: Narcolepsy is a neurological/sleep disorder, not a psychiatric condition—but PMHNPs are well-positioned to treat it because:

1. You’re already familiar with stimulants (used in ADHD)
2. Many narcolepsy patients have comorbid depression, anxiety, or ADHD
3. Some narcolepsy medications (SSRIs/SNRIs for cataplexy) are standard psychiatric meds

That said, you should practice within your competency. If you’re managing narcolepsy, you need to be comfortable interpreting sleep studies (polysomnography, Multiple Sleep Latency Tests), understanding differential diagnoses (idiopathic hypersomnia, sleep apnea), and coordinating with sleep specialists when cases are complex.

Malpractice insurance: Verify with your carrier that treating narcolepsy falls under your covered scope. It usually does for PMHNPs, but you may need to demonstrate specific training or experience if challenged.

Narcolepsy-Specific Regulatory Challenges

Diagnostic Requirements and Telehealth

Confirming a narcolepsy diagnosis typically requires:

• Overnight polysomnography (sleep study) to rule out sleep apnea and other conditions
• Multiple Sleep Latency Test (MSLT) to measure daytime sleepiness and REM sleep onset

These tests are almost always done in-person at a sleep lab. If you’re running a pure telehealth practice, you’ll need to:

• Coordinate referrals to local sleep centers for diagnostic testing
• Review and interpret results remotely
• Integrate those findings into your treatment plan

This isn’t a legal barrier—it’s a practical workflow challenge. Some telehealth platforms partner with sleep testing companies or local sleep medicine practices to streamline this process.

Sodium Oxybate (Xyrem, Xywav) REMS Requirements

Sodium oxybate is a Schedule III medication used for narcolepsy with cataplexy. It’s also subject to an FDA Risk Evaluation and Mitigation Strategy (REMS) program, which means:

• You must enroll in the REMS program to prescribe it
• Patients must be enrolled and counseled on risks (abuse potential, respiratory depression)
• Dispensing is restricted to specialty pharmacies

If you’re treating narcolepsy patients who need sodium oxybate, factor in the administrative overhead of REMS compliance. This is doable via telehealth, but it’s not as simple as e-prescribing a stimulant.

State Formulary Rules and Approved Indications

Some states explicitly list narcolepsy as an approved indication for stimulant prescribing—this is useful legally. For example, Florida’s medical practice regulations specify that prescribing Schedule II amphetamines is lawful for narcolepsy, ADHD, epilepsy, or refractory depression (www.flsenate.gov). This protects you from allegations of inappropriate prescribing if you can document the diagnosis.

Documentation is everything: Make sure your chart clearly shows:

• Symptom history (excessive daytime sleepiness, cataplexy, sleep paralysis)
• Sleep study results confirming diagnosis
• Clinical rationale for medication choice and dose
• Informed consent discussion (including abuse potential, side effects)
• Regular monitoring and follow-up plans

This isn’t just good medicine—it’s essential legal protection when prescribing controlled substances remotely.

The Economics: Why Telehealth Platforms Make Sense for Narcolepsy Care

Let’s talk about the business case, because that’s what actually determines whether you can build a sustainable practice.

The DIY Marketing Reality

If you’re building a solo or small-group practice and trying to attract narcolepsy patients on your own, here’s what you’re up against:

SEO/Content Marketing: Takes 6-12 months of consistent investment before you see meaningful patient flow. You need a website, blog content targeting narcolepsy-specific keywords, backlinks, and technical SEO optimization. Most providers don’t have the expertise or patience for this.

Google Ads: Mental health and sleep disorder keywords are expensive—$15-40+ per click. Most clicks don’t convert to booked patients. By the time you factor in ad spend, agency/consultant fees, and your time qualifying leads, you’re looking at $200-400+ cost per booked patient (and that’s if your campaigns are well-optimized).

Directory Listings: Psychology Today, Zocdoc, and other directories charge monthly subscription fees ($30-200+/month) and you’re competing with hundreds of other providers on the same page. Zocdoc also charges per booking ($35-100+ depending on specialty). Total monthly cost including subscriptions adds up quickly.

Reality check: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you include all costs—ad spend, consultant fees, staff time to handle and qualify leads, no-show rates from cold leads, months of SEO investment, and failed campaigns. And narcolepsy patients are even harder to reach because it’s a rare condition (affects ~1 in 2,000 people).

The Platform Alternative: Klarity Health’s Model

Klarity Health uses a pay-per-appointment model (similar to Zocdoc) where you pay a standard listing fee per new patient lead who books with you. Here’s why this makes economic sense:

No upfront marketing spend: You don’t pay $3,000-5,000/month on marketing with uncertain results. You pay only when a qualified patient books an appointment.

Pre-qualified patients: Klarity’s intake process matches patients to providers based on specialty, availability, and insurance. You’re not wasting time on tire-kickers or people who aren’t a good fit.

No wasted ad spend: You’re not gambling on which keywords or ad copy will convert. Klarity handles patient acquisition at scale.

Built-in telehealth infrastructure: You don’t need to pay for separate EHR, scheduling, video platform, and e-prescribing tools. It’s all included.

Both insurance and cash-pay flow: Klarity credentialed providers with major insurance panels, which means you can see both insured patients (typically higher lifetime value) and cash-pay patients.

You control your schedule: Set your availability, accept the patients you want to see, and scale up or down based on your capacity. You’re not locked into a minimum patient volume or monthly fees.

The ROI case: Instead of spending $3,000-5,000/month on marketing channels that might generate 10-15 new patients (if you’re lucky and experienced), you pay a predictable fee per booked patient—and you know it’s a real appointment, not a click or a lead that goes nowhere.

For narcolepsy specifically, where patient acquisition is even harder (it’s a niche specialty with low search volume), having a platform that already has patient flow and matches based on diagnosis makes the difference between a viable practice and struggling to fill your schedule.

What to Do Next: Building a Compliant Narcolepsy Telehealth Practice

If you’re a psychiatrist:

1. Get licensed in multiple states via the Interstate Medical Licensure Compact (IMLC) if available—IL, TX, and PA are members. For CA, NY, and FL, use traditional licensing.
2. Verify your DEA registration includes Schedule II authority and covers all states where you’re licensed.
3. Set up PDMP access in each state you practice (this is required before prescribing controlled substances).
4. Partner with local sleep centers for diagnostic testing referrals if you’re doing pure telehealth.
5. Document thoroughly: Your telehealth exam notes should be as detailed as in-person visits, especially when prescribing controlled substances.

If you’re a PMHNP:

1. Know your state’s scope limits and work within them. If you’re in TX or FL, you’ll need physician collaboration for stimulant prescriptions. If you’re in CA, NY, or IL and meet experience requirements, you can practice independently.
2. Pursue FPA status if you’re in a state that offers it (CA, NY, IL)—the autonomy is worth the extra hours of supervised practice.
3. Coordinate with physicians if you’re in a collaborative state. Make sure your agreement explicitly covers narcolepsy diagnosis and controlled substance prescribing.
4. Complete required training: For Schedule II authority in CA, complete the BRN-specified pharmacology coursework. For FPA in IL, complete the 250 hours of continuing education in psychiatric mental health.

For both:

• Stay updated on DEA rulemaking. Sign up for DEA and HHS announcements, and monitor professional association guidance (APA, AANP, APNA). When the permanent telehealth rules are finalized, you’ll need to adjust quickly.
• Plan for a hybrid model. Even if you’re doing telehealth now, start thinking about how you’ll incorporate periodic in-person visits or partnerships when the DEA requires them.
• Consider joining a platform like Klarity Health. Platforms handle patient acquisition, credentialing, billing, and compliance infrastructure—letting you focus on clinical care instead of marketing and admin overhead.

The Bottom Line

Can you prescribe narcolepsy medications via telehealth? Yes—for now, through the end of 2026. The DEA’s COVID-era flexibilities give you a clear runway to build a telehealth practice treating narcolepsy with stimulants, modafinil, and other controlled medications.

But the rules are temporary and state-dependent. Florida’s telehealth ban on Schedule IIs for non-psychiatric conditions is a real barrier. Texas’s prohibition on NP prescribing of Schedule IIs for outpatients means you need MDs on your team. New York, California, and Illinois offer the most flexibility—especially for experienced PMHNPs with full practice authority.

The smart move is to build for compliance now and prepare for stricter rules later. That means thorough documentation, coordinated care with in-person sleep testing, and partnership models that can adapt when the DEA finalizes permanent telemedicine regulations.

And if you’re trying to attract narcolepsy patients on your own, you’re competing in a difficult, expensive market. Platforms like Klarity Health solve the patient acquisition problem by handling marketing, intake, and matching at scale—letting you pay only for qualified appointments instead of gambling on SEO and Google Ads.

The opportunity to expand access to narcolepsy care via telehealth is real. The regulatory path is navigable. The question is whether you want to spend your time figuring out Facebook Ads and PDMP integrations, or whether you’d rather see patients.

Ready to explore joining Klarity Health’s provider network? Learn how we handle patient acquisition, credentialing, and compliance so you can focus on what you do best—helping patients get the sleep disorder treatment they desperately need.

FAQ

Can I prescribe Adderall for narcolepsy via telehealth in 2026?
Yes, under current federal DEA rules (extended through December 31, 2026), you can prescribe Schedule II stimulants like Adderall for narcolepsy via telehealth without an in-person exam—except in states with additional restrictions. Florida explicitly bans telehealth prescribing of Schedule IIs for non-psychiatric conditions, which includes narcolepsy. In all other states (CA, TX, NY, PA, IL), you can prescribe stimulants via telehealth as long as you comply with state PDMP and e-prescribing requirements.

Do PMHNPs need a collaborating physician to treat narcolepsy?
It depends on the state. In full practice authority states like California (for experienced NPs), New York (after 3,600 hours), and Illinois (after 4,000 hours + extra training), PMHNPs can diagnose and treat narcolepsy independently. In restricted states like Texas and Pennsylvania, you need a collaborating physician—and in Texas, NPs cannot prescribe Schedule II stimulants at all in outpatient settings. Florida requires collaboration and limits NP Schedule II prescriptions to 7 days for non-psychiatric conditions.

What happens to telehealth prescribing after the DEA waiver expires in 2026?
The DEA is finalizing permanent telemedicine rules, which will likely require some in-person component—possibly an initial exam within 30-90 days or periodic in-person visits for ongoing controlled substance prescriptions. The exact requirements aren’t set yet, but providers should prepare for stricter rules by building hybrid care models or partnering with local clinics for in-person exams and diagnostic testing.

Can I prescribe narcolepsy medications across state lines via telehealth?
Yes, but only if you hold an active medical or nursing license in the state where the patient is physically located at the time of the telehealth visit. You also need DEA registration that covers that state. Many providers obtain licenses in multiple states (via the Interstate Medical Licensure Compact for physicians, or individual state applications) to expand their patient base. Platforms like Klarity Health help coordinate multi-state licensing and credentialing.

What’s the cost to acquire a narcolepsy patient through DIY marketing vs. a platform?
DIY marketing (Google Ads, SEO, directory listings) typically costs $200-500+ per booked patient when you factor in all costs: ad spend, consultant fees, staff time, no-shows from cold leads, and months of investment before results. Narcolepsy is a rare condition with low search volume, making patient acquisition even harder. Platforms like Klarity Health use a pay-per-appointment model where you pay a listing fee only when a qualified patient books with you—eliminating wasted ad spend and guaranteeing ROI.

Do I need special certification to treat narcolepsy as a psychiatrist or PMHNP?
No special certification is required by law, but you should practice within your competency. Treating narcolepsy requires understanding sleep study interpretation (polysomnography, MSLT), differential diagnoses (idiopathic hypersomnia, sleep apnea), and medication management (stimulants, sodium oxybate, SSRIs for cataplexy). Many providers pursue continuing education in sleep medicine or consult with neurologists/sleep specialists for complex cases. Your malpractice insurance may require you to demonstrate relevant training or experience.

How do I coordinate sleep studies for telehealth narcolepsy patients?
Partner with local sleep centers in the states where your patients are located. You can order polysomnography and MSLT remotely, then review the results and integrate them into your treatment plan via telehealth follow-up. Some telehealth platforms (including Klarity Health) maintain referral networks with sleep testing facilities to streamline this process.

What are the PDMP requirements for prescribing narcolepsy medications?
Every state requires you to check the state prescription drug monitoring program (PDMP) before prescribing controlled substances. Requirements vary:

• California: Check CURES before first Schedule II-IV prescription and at least every 4 months for ongoing therapy
• Texas: Check Texas PMP before any controlled prescription
• Florida: Check E-FORCSE for all controlled prescriptions (mandatory)
• New York: Check I-STOP before every controlled prescription
• Pennsylvania: Check PA PDMP before each prescription
• Illinois: Check ILPMP before prescribing opioids and other designated controlled substances (includes stimulants)

Most telehealth EHR platforms integrate PDMP checking into the e-prescribing workflow.

References

1. U.S. Department of Health & Human Services (HHS). ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. www.hhs.gov

2. Drug Enforcement Administration (DEA). ‘DE

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206